Ripretinib – KIT and PDGFRA inhibitor
Gastrointestinal stromal tumor (GIST)
About This Program
Based on an exploratory ctDNA analysis from the Phase 3 INTRIGUE study, ripretinib is being investigated in the INSIGHT study. INSIGHT is a Phase 3, randomized, global, multicenter, open-label study to evaluate the efficacy and safety of ripretinib compared to sunitinib in patients with advanced GIST previously treated with imatinib with mutations in KIT exon 11 and 17/18 (excluding patients with mutations in KIT exons 9, 13, or 14). In the study, 54 patients will be randomized 2:1 to either ripretinib 150 mg once daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off).
To learn more about this study, click here.
To learn more about the study rationale of INSIGHT, click here.
References
Heinrich MC, Jones RL, George S, et al. Nat Med. 2024;30(2):498-506. doi:10.1038/s41591-023-02734-5